L'Aztréonam est-il «un challenger» possible pour le traitement des infections à Gram négatif? Tentative de réponse à partir des données microbiologiques: étude in vitro concernant 36485 entérobactéries et Pseudomonas
Authors:
- P. HonderlickPHP. Honderlick
- J. GravisseJGJ. Gravisse
- D. DardelleDDD. Dardelle
- P. CahenPCP. Cahen
- 31 December 2007
- journal article
- abstracts
- Published by Elsevier in Pathologie Biologie
- Vol. 55 (10) , 475-477
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo SimulationAntimicrobial Agents and Chemotherapy, 2007
- Use of 27 parenteral antimicrobial agents in north of France hospitalsMedecine Et Maladies Infectieuses, 2007
- Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patientsClinical Therapeutics, 2001
- Aztreonam: A Review of the First MonobactamThe American Journal of the Medical Sciences, 1991